349 related articles for article (PubMed ID: 18484682)
21. Epigenetic alteration at the DLK1-GTL2 imprinted domain in human neoplasia: analysis of neuroblastoma, phaeochromocytoma and Wilms' tumour.
Astuti D; Latif F; Wagner K; Gentle D; Cooper WN; Catchpoole D; Grundy R; Ferguson-Smith AC; Maher ER
Br J Cancer; 2005 Apr; 92(8):1574-80. PubMed ID: 15798773
[TBL] [Abstract][Full Text] [Related]
22. Loss of imprinting of insulin-like growth factor-II (IGF2) gene in distinguishing specific biologic subtypes of Wilms tumor.
Ravenel JD; Broman KW; Perlman EJ; Niemitz EL; Jayawardena TM; Bell DW; Haber DA; Uejima H; Feinberg AP
J Natl Cancer Inst; 2001 Nov; 93(22):1698-703. PubMed ID: 11717330
[TBL] [Abstract][Full Text] [Related]
23. CTNNB1 mutations and overexpression of Wnt/beta-catenin target genes in WT1-mutant Wilms' tumors.
Li CM; Kim CE; Margolin AA; Guo M; Zhu J; Mason JM; Hensle TW; Murty VV; Grundy PE; Fearon ER; D'Agati V; Licht JD; Tycko B
Am J Pathol; 2004 Dec; 165(6):1943-53. PubMed ID: 15579438
[TBL] [Abstract][Full Text] [Related]
24. Pathology, genetics and cytogenetics of Wilms' tumour.
Md Zin R; Murch A; Charles A
Pathology; 2011 Jun; 43(4):302-12. PubMed ID: 21516053
[TBL] [Abstract][Full Text] [Related]
25. Role of genomic imprinting in Wilms' tumour and overgrowth disorders.
Reeve AE
Med Pediatr Oncol; 1996 Nov; 27(5):470-5. PubMed ID: 8827076
[TBL] [Abstract][Full Text] [Related]
26. Nephron Progenitor But Not Stromal Progenitor Cells Give Rise to Wilms Tumors in Mouse Models with β-Catenin Activation or Wt1 Ablation and Igf2 Upregulation.
Huang L; Mokkapati S; Hu Q; Ruteshouser EC; Hicks MJ; Huff V
Neoplasia; 2016 Feb; 18(2):71-81. PubMed ID: 26936393
[TBL] [Abstract][Full Text] [Related]
27. Loss of imprinting of IGF2 sense and antisense transcripts in Wilms' tumor.
Vu TH; Chuyen NV; Li T; Hoffman AR
Cancer Res; 2003 Apr; 63(8):1900-5. PubMed ID: 12702581
[TBL] [Abstract][Full Text] [Related]
28. WT1, WTX and CTNNB1 mutation analysis in 43 patients with sporadic Wilms' tumor.
Cardoso LC; De Souza KR; De O Reis AH; Andrade RC; Britto AC; De Lima MA; Dos Santos AC; De Faria PS; Ferman S; Seuánez HN; Vargas FR
Oncol Rep; 2013 Jan; 29(1):315-20. PubMed ID: 23117548
[TBL] [Abstract][Full Text] [Related]
29. Changes in WT1 splicing are associated with a specific gene expression profile in Wilms' tumour.
Baudry D; Faussillon M; Cabanis MO; Rigolet M; Zucker JM; Patte C; Sarnacki S; Boccon-Gibod L; Junien C; Jeanpierre C
Oncogene; 2002 Aug; 21(36):5566-73. PubMed ID: 12165855
[TBL] [Abstract][Full Text] [Related]
30. Insulin-like growth factor II and WT1 transcript localization in human fetal kidney and Wilms' tumor.
Yun K; Fidler AE; Eccles MR; Reeve AE
Cancer Res; 1993 Nov; 53(21):5166-71. PubMed ID: 8221652
[TBL] [Abstract][Full Text] [Related]
31. Age distributions, birth weights, nephrogenic rests, and heterogeneity in the pathogenesis of Wilms tumor.
Breslow NE; Beckwith JB; Perlman EJ; Reeve AE
Pediatr Blood Cancer; 2006 Sep; 47(3):260-7. PubMed ID: 16700047
[TBL] [Abstract][Full Text] [Related]
32. Genomic imprinting at the WT1 gene involves a novel coding transcript (AWT1) that shows deregulation in Wilms' tumours.
Dallosso AR; Hancock AL; Brown KW; Williams AC; Jackson S; Malik K
Hum Mol Genet; 2004 Feb; 13(4):405-15. PubMed ID: 14681303
[TBL] [Abstract][Full Text] [Related]
33. Gene expression profiling of favorable histology Wilms tumors and its correlation with clinical features.
Takahashi M; Yang XJ; Lavery TT; Furge KA; Williams BO; Tretiakova M; Montag A; Vogelzang NJ; Re GG; Garvin AJ; Söderhäll S; Kagawa S; Hazel-Martin D; Nordenskjold A; Teh BT
Cancer Res; 2002 Nov; 62(22):6598-605. PubMed ID: 12438255
[TBL] [Abstract][Full Text] [Related]
34. Single-nucleotide polymorphism in WT1 gene in a hyperplastic intralobar nephrogenic rest with botryoid protrusion.
Mizuno K; Hayashi Y; Tozawa K; Iwatsuki S; Kojima Y; Kohri K
Urology; 2010 Jul; 76(1):149-52. PubMed ID: 19914700
[TBL] [Abstract][Full Text] [Related]
35. Two molecular subgroups of Wilms' tumors with or without WT1 mutations.
Schumacher V; Schuhen S; Sonner S; Weirich A; Leuschner I; Harms D; Licht J; Roberts S; Royer-Pokora B
Clin Cancer Res; 2003 Jun; 9(6):2005-14. PubMed ID: 12796362
[TBL] [Abstract][Full Text] [Related]
36. High incidence of loss of heterozygosity and abnormal imprinting of H19 and IGF2 genes in invasive cervical carcinomas. Uncoupling of H19 and IGF2 expression and biallelic hypomethylation of H19.
Douc-Rasy S; Barrois M; Fogel S; Ahomadegbe JC; Stéhelin D; Coll J; Riou G
Oncogene; 1996 Jan; 12(2):423-30. PubMed ID: 8570220
[TBL] [Abstract][Full Text] [Related]
37. Upregulation of c-MYC in WT1-mutant tumors: assessment of WT1 putative transcriptional targets using cDNA microarray expression profiling of genetically defined Wilms' tumors.
Udtha M; Lee SJ; Alam R; Coombes K; Huff V
Oncogene; 2003 Jun; 22(24):3821-6. PubMed ID: 12802290
[TBL] [Abstract][Full Text] [Related]
38. Epigenetic specificity of loss of imprinting of the IGF2 gene in Wilms tumors.
Bjornsson HT; Brown LJ; Fallin MD; Rongione MA; Bibikova M; Wickham E; Fan JB; Feinberg AP
J Natl Cancer Inst; 2007 Aug; 99(16):1270-3. PubMed ID: 17686827
[TBL] [Abstract][Full Text] [Related]
39. Altered expression of imprinted genes in Wilms tumors.
Hubertus J; Lacher M; Rottenkolber M; Müller-Höcker J; Berger M; Stehr M; von Schweinitz D; Kappler R
Oncol Rep; 2011 Mar; 25(3):817-23. PubMed ID: 21174059
[TBL] [Abstract][Full Text] [Related]
40. Different CTNNB1 mutations as molecular genetic proof for the independent origin of four Wilms tumours in a patient with a novel germ line WT1 mutation.
Uschkereit C; Perez N; de Torres C; Küff M; Mora J; Royer-Pokora B
J Med Genet; 2007 Jun; 44(6):393-6. PubMed ID: 17551084
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
